Heres what that may look like for each medication: Semaglutide: Weeks 1-4: 0.25 mg/week Weeks 5-8: 0.5 mg/week Weeks 9-12: 1.0 mg/week Weeks 13-16: 1.75 mg/week Week 17 and beyond: 2.5 mg/week Tirzepatide: Weeks 1-4: 2.5 mg/week Weeks 5-8: 5.0 mg/week Weeks 9-12: 7.5 mg/week Weeks 13-16: 10 mg/week In some cases, patients may increase to 12.5 mg or 15 mg per week if needed
Although weight loss injectables are not directly associated with DVT, its use in patients with multiple risk factors for clotting disorders, such as obesity or prolonged immobility, may increase that risk unnecessarily
A treatment strategy based on stricter glucose control, intended to reduce glycated hemoglobin (HbA1c) levels to close to those of a person without diabetes, has been shown to reduce mortality and the appearance of micro- and macrovascular complications in people with DM (46)
The obesity segment, however, presents a unique situation, with far less public funding, and evolving treatment norms
Or patients can have a body fat % of 30+ for females or 25+ for males
Adjusting antihypertensive doses early often prevents this issue